8-K/A: Neuronetics Corrects Cash Flow Breakeven Target to Third Quarter 2025 Following Greenbrook TMS Acquisition

Neuronetics has revised its cash flow breakeven target to the third quarter of 2025, following the approval of its acquisition of Greenbrook TMS.

Summary

• Neuronetics has amended its previous 8-K filing to clarify that it expects to achieve cash flow breakeven by the third quarter of 2025, not the second quarter.
• This correction follows the approval of Neuronetics' acquisition of Greenbrook TMS by Neuronetics stockholders on November 8, 2024.
• The company reported third quarter 2024 revenue of $18.5 million, a 4% increase compared to the same period in 2023.
• U.S. NeuroStar Advanced Therapy system revenue was $4.1 million, representing 48 systems sold.
• U.S. treatment session revenue increased by 2% year-over-year.
• The company has treated over 188,000 global patients with 6.9 million treatment sessions.
• Gross margin for the third quarter of 2024 was 75.6%, up from 65.8% in the third quarter of 2023.
• Operating expenses for the third quarter of 2024 were $21.7 million, a 5% increase year-over-year.
• Net loss for the third quarter of 2024 was $(13.3) million, or $(0.44) per share, compared to $(9.4) million, or $(0.33) per share, in the third quarter of 2023.
• EBITDA for the third quarter of 2024 was $(11.6) million, compared to $(7.7) million in the third quarter of 2023.
• Cash and cash equivalents were $20.9 million as of September 30, 2024, down from $59.7 million at the end of 2023.
• The company expects total worldwide revenue between $19.0 million and $20.0 million for the fourth quarter of 2024.
• For the full year 2024, the company expects total worldwide revenue to be between $71.0 million and $72.0 million and total operating expenses to be between $81.0 million and $82.0 million, excluding pre-closing transaction costs of approximately $2.0 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects such as revenue growth, improved gross margin, and the strategic acquisition, the increased net loss and negative EBITDA, along with the cash burn, temper the overall sentiment. The correction of the cash flow breakeven target also introduces some uncertainty.

Positives

• Revenue increased by 4% year-over-year to $18.5 million in the third quarter of 2024.
• U.S. NeuroStar Advanced Therapy system revenue increased by 14% year-over-year to $4.1 million.
• Gross margin improved significantly to 75.6% in the third quarter of 2024.
• The acquisition of Greenbrook TMS is expected to create a vertically integrated organization with significant scale.
• Clinical data shows strong efficacy of NeuroStar TMS in treating adolescent depression, with a 78% response rate and 48% remission rate.
• The company has a large number of patients treated with 6.9 million treatment sessions.

Negatives

• Net loss for the third quarter of 2024 was $(13.3) million, an increase from $(9.4) million in the same period last year.
• EBITDA for the third quarter of 2024 was $(11.6) million, compared to $(7.7) million in the third quarter of 2023.
• Cash and cash equivalents decreased significantly from $59.7 million at the end of 2023 to $20.9 million as of September 30, 2024.
• Operating expenses increased by 5% year-over-year to $21.7 million in the third quarter of 2024.
• International revenue decreased by 10% year-over-year.

Risks

• The company's ability to achieve cash flow breakeven by the third quarter of 2025 is subject to execution risks.
• The integration of Greenbrook TMS may present challenges and unexpected costs.
• The company faces risks related to maintaining Nasdaq listing requirements.
• There are risks associated with the combined company's ability to sell its products and the market reception to its products.
• The company's ability to manage growth and obtain additional financing is uncertain.
• The company faces competition in its industry and must protect its intellectual property.
• The company's business is subject to regulatory changes and legal proceedings.
• The company's revenue is concentrated among a small number of customers.

Future Outlook

The company expects total worldwide revenue between $19.0 million and $20.0 million for the fourth quarter of 2024 and between $71.0 million and $72.0 million for the full year 2024. The company also expects total operating expenses to be between $81.0 million and $82.0 million for the full year 2024, excluding pre-closing transaction costs of approximately $2.0 million. Neuronetics expects to achieve cash flow breakeven by the third quarter of 2025.

Management Comments

• Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, stated that the acquisition of Greenbrook TMS positions Neuronetics to be one of the largest and most innovative providers of mental health care in the United States.
• He also mentioned that the strategic combination will enhance the company's ability to expand access to mental health solutions and accelerate the rollout of additional services.
• Sullivan noted continued progress across strategic initiatives in the third quarter, including strong momentum in the adolescent treatment program and encouraging early results from targeted marketing efforts.

Industry Context

This announcement comes as the mental health industry is seeing increased focus on innovative treatments and consolidation. The acquisition of Greenbrook TMS by Neuronetics is a move towards creating a larger, more integrated player in the market, which aligns with the trend of companies seeking to expand their reach and service offerings. The presentation of positive clinical data for adolescent depression treatment also highlights the growing importance of addressing mental health issues in younger populations.

Comparison to Industry Standards

• Neuronetics' revenue growth of 4% is moderate compared to some high-growth medical technology companies, but it is important to consider the specific market for TMS therapy.
• The gross margin of 75.6% is strong and indicates efficient cost management, which is a positive sign compared to industry averages.
• The net loss and negative EBITDA highlight the company's ongoing challenges with profitability, which is not uncommon for companies in the growth phase of the medical device sector.
• Companies like Magstim and Brainsway are competitors in the TMS market, and their financial performance and market share would be relevant benchmarks for comparison.
• The acquisition of Greenbrook TMS is a significant strategic move, and its success will be measured against similar consolidation efforts in the healthcare industry.

Stakeholder Impact

• Shareholders will be impacted by the acquisition of Greenbrook TMS and the revised cash flow breakeven target.
• Employees may experience changes due to the integration of the two companies.
• Customers will benefit from increased access to mental health treatment and a broader range of services.
• Suppliers may see changes in their relationships with the combined company.
• Creditors will be impacted by the company's financial performance and debt levels.

Next Steps

• The next step in finalizing the Greenbrook TMS acquisition is a hearing in respect of the Final Order pursuant to the Ontario Business Corporations Act scheduled for November 15, 2024.
• The company will focus on integrating Greenbrook TMS and optimizing the combined operations.
• Neuronetics will continue to implement its strategic initiatives, including the Better Me Provider Program and the rollout of SPRAVATO treatment.

Key Dates

Keywords

Neuronetics, Greenbrook TMS, TMS, NeuroStar, Mental Health, Acquisition, Cash Flow Breakeven, Revenue, EBITDA, Gross Margin, Depression, Adolescent Treatment